Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cizutamig - Candid Therapeutics/EpimAB Biotherapeutics

Next Previous
Drug Profile

Cizutamig - Candid Therapeutics/EpimAB Biotherapeutics

Alternative Names: CND-106; EMB-06

Latest Information Update: 09 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpimAb Biotherapeutics
  • Developer Candid Therapeutics; EpimAb Biotherapeutics
  • Class Antineoplastics; Antirheumatics; Bispecific antibodies; Immunotherapies; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Phase I IgA nephropathy; Myasthenia gravis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Clinical Phase Unknown Systemic scleroderma

Most Recent Events

  • 02 Mar 2026 Candid Therapeutics plans a global phase II trials for Myasthenia gravis and Interstitial lung disease (Parenteral) in 2026
  • 13 Feb 2026 Candid Therapeutics plans a phase I trial for Immediate hypersensitivity in Australia (SC) in March 2026 (NCT07408869)
  • 20 Jan 2026 Ruijin Hospital plans a phase I trial for Ulcerative colitis (Treatment-experienced) in China (IV) in January 2026 (NCT07353450)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top